Electroacupuncture alleviates myocardial ischemia-reperfusion injury by targeting and inhibiting NLRP3 inflammasome-mediated cardiomyocyte pyroptosis via serum exosomal miR-22-3p
-
By
-
Jian Xiong
-
Ying Wei
-
Yunnan Liu
-
Fayang Ling
-
Yi Zhao
-
Yu Liu
-
Yuxin Sun
-
Dehua Li
-
Mingsheng Sun
-
Dingjun Cai
-
Wenchuan Qi
-
Qianhua Zheng
-
Fanrong Liang
-
June 1, 2026
-
Clinical Scorecard: Electroacupuncture Reduces Myocardial Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome-Driven Pyroptosis in Cardiomyocytes Through Serum Exosomal miR-22-3p
At a Glance
| Category | Detail |
|---|
| Condition | Myocardial Ischemia-Reperfusion Injury (MIRI) |
| Key Mechanisms | NLRP3 inflammasome-mediated cardiomyocyte pyroptosis |
| Target Population | Patients with acute myocardial infarction (AMI) and severe ischemic heart disease |
| Care Setting | Clinical and experimental settings involving reperfusion therapy |
Key Highlights
- Electroacupuncture (EA) mitigates MIRI by targeting NLRP3-mediated myocardial apoptosis.
- Serum exosomal miR-22-3p is upregulated following EA and inhibits cardiomyocyte pyroptosis.
- NLRP3 inflammasome activation is a central pathological mechanism in MIRI.
- EA was applied at the Neiguan (PC6) acupoint in an animal model of MIRI.
Guideline-Based Recommendations
Diagnosis
- Assessment of myocardial infarction area and cardiac function using echocardiography.
Management
- Utilization of electroacupuncture as a complementary treatment for MIRI.
Monitoring & Follow-up
- Measurement of serum myocardial enzymes and inflammatory factors.
Risks
- Potential secondary damage to myocardial function due to reperfusion therapy.
Patient & Prescribing Data
Patients undergoing reperfusion therapy for AMI.
Electroacupuncture may enhance recovery by modulating inflammatory responses.
Clinical Best Practices
- Monitor serum exosomal miR-22-3p levels as a potential biomarker for treatment efficacy.
Related Resources & Content
